CAM-TRT 2

CAM-TRT 2 is a preclinical-stage radiopharmaceutical being developed by Precirix. It consists of a single-domain antibody (sdAb), also known as a nanobody, conjugated to a therapeutic radioisotope. The single-domain antibody serves as a targeting vehicle designed to bind to a specific, currently undisclosed, biological target, facilitating the delivery of ionizing radiation directly to tumor cells. This approach aims to maximize therapeutic efficacy while minimizing systemic toxicity. As of early 2024, the specific target and primary indications for CAM-TRT 2 remain proprietary and undisclosed by the developer, though it is part of a pipeline focused on treating solid tumors.